Search

Shahnaz H Dairkee

from Orinda, CA
Age ~73
Get Report
Also known as:
Shahnaz S Dairkee, Shanaz H Dairkee, V E, Shahnaz E
Phone and address:
5 Culver Ct, Orinda, CA 94563
(925) 254-9068
Related to:
Janet E Jones, 81Bridget Goetz, 47Fred Hill, 63Dylon Jones, 53Robert Walsh, 81Reginald B Baxter, 62
Connected to:
Aneela Dairkee, 60Rosalie G Dairo, 60Beverly L Dairsow, 64Latasha E Dairy, 38Barbara A Dais, 61Frederick L Dais, 53Gina L Dais, 64Irene Dais, 73Jenna M Dais, 30Mark C Dais, 56

Shahnaz Dairkee Phones & Addresses

  • 5 Culver Ct, Orinda, CA 94563 (925) 254-9068
  • Stockton, CA
  • 1320 Puebla Way, Roseville, CA 95747
  • Pittsburg, CA

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Publications

Us Patents

Hybridoma Cell Line Xmmbr-B14 And Monoclonal Antibody Which Is Specific For A Non-Cross Reactive Epitope Of Cea

View page
US Patent:
48534641, Aug 1, 1989
Filed:
Feb 16, 1988
Appl. No.:
7/158086
Inventors:
Adeline J. Hackett - Orinda CA
Shahnaz H. Dairkee - Orinda CA
Assignee:
Peralta Cancer Research Institute - Oakland CA
International Classification:
A61K 39395
C07K 1514
C12N 1500
US Classification:
530387
Abstract:
The present invention provides a novel hybridoma cell line secreting monoclonal antibodies (MoAbs) that define an epitope found on an antigen of the classification termed CEA/NCA (carcinoembryonic antigen/normal cross-reacting antigen). The MoAbs of the invention find particular utility as the targeting moiety of immunotoxin and immunoimaging conjugates. Hybridoma XMMBR-B14 was deposited with the A. T. C. C. on Jan. 14, 1987 and given A. T. C. C. Accession No. HB 9308.

Composition Containing Cea/Nca-Specific Monoclonal Antibody Xmmbr-B14 Conjugated To A Detectable Moiety And A Kit Containing The Antibody

View page
US Patent:
52255417, Jul 6, 1993
Filed:
Aug 1, 1989
Appl. No.:
7/388543
Inventors:
Adeline J. Hackett - Orinda CA
Shahnaz H. Dairkee - Orinda CA
Assignee:
Peralta Cancer Research Institute - San Leandro CA
International Classification:
C07K 1528
C12N 520
A61K 4300
G01N 3353
US Classification:
5303913
Abstract:
The present invention provides a composition consisting of a monoclonal antibody that defines an epitope found on an antigen antigen/normal cross-reacting antigen produced by hybridoma XMMBR-B14 (HB 9308) conjugated to a detectable moiety, and a kit containing the antibody. Hybridoma XMMBR-B14 was deposited with the ATCC on Jan. 14, 1987 and given the ATCC Accession No. HB 9308.

Methods And Compositions For Screening Carcinomas

View page
US Patent:
51588935, Oct 27, 1992
Filed:
Apr 17, 1990
Appl. No.:
7/511806
Inventors:
Adeline J. Hackett - Orinda CA
Shahnaz H. Dairkee - Orinda CA
Assignee:
Peralta Cancer Research Institute - San Leandro CA
International Classification:
C07K 1528
G01N 33574
G01N 33577
US Classification:
435721
Abstract:
Methods for determining the prognosis of human carcinomas utilizing a marker specific for malignant cells of aggressive cancers. Cell lines have been produced that secrete monoclonal antibodies useful in detecting such markers, including a 51,000-dalton keratin protein, specific for myoepithelial cells, e. g. , in tissue culture. Pharmaceutical compositions containing these antibodies, which can be in combination with cytotoxic agents and the use of such compositions in the management of carcinomas are included. Prior to filing of this patent application, the continuous transformed cell lines described herein was deposited in the American Type Culture Collection and designated Accession No. HB9288.
Control profile
Shahnaz H Dairkee from Orinda, CA, age ~73 Get Report